Consistency in the Chaos: FDA Approvals Within Average Range as Q4 Kicks Off
Heading into the final quarter of a year that has seen dramatic upheaval at the FDA—from the exodus of numerous senior leaders to unclear policy changes and a safety saga that engulfed the gene therapy space—drug approvals appear roughly on par with recent years.
Consistency in the Chaos: FDA Approvals Within Average Range as Q4 Kicks Off Read More »
